Related Experiment Video
Updated: Aug 6, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion
Seong Hwan Choi1, Eun Young Park, Hye Lim Jung
1Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Jongro-gu, Seoul, Korea.
Insights
Serum vascular endothelial growth factor (VEGF) levels are elevated in children with community-acquired pneumonia, particularly in lobar pneumonia cases. Higher VEGF indicates more severe pneumonia and potential parapneumonic effusion.
Area of Science:
- Pediatric Pulmonology
- Immunology
- Biochemistry
Background:
- Community-acquired pneumonia (CAP) is a significant pediatric illness.
- Vascular Endothelial Growth Factor (VEGF) plays a role in inflammation and angiogenesis.
- Understanding inflammatory markers in pediatric pneumonia is crucial for diagnosis and management.
Purpose of the Study:
- To investigate serum VEGF levels in children diagnosed with community-acquired pneumonia.
- To compare VEGF levels between pneumonia patients and healthy controls.
- To explore the correlation of VEGF with pneumonia severity and specific etiological factors.
Main Methods:
- Serum samples from 29 children with pneumonia and 27 controls were analyzed.
- Sandwich enzyme-linked immunosorbent assay (ELISA) was used to measure serum VEGF levels.
- Chest radiographs classified pneumonia types; IL-6 and inflammatory markers were also assessed.
Main Results:
- Children with pneumonia exhibited significantly higher serum VEGF levels than controls (p<0.01).
- Lobar pneumonia cases showed higher VEGF than bronchopneumonia cases.
- Elevated VEGF correlated with positive Streptococcus pneumoniae antigen tests and higher erythrocyte sedimentation rates.
Conclusions:
- Serum VEGF is a potential biomarker for pediatric community-acquired pneumonia.
- VEGF levels may indicate disease severity, particularly in lobar pneumonia and cases with pleural effusion.
- VEGF might be a key mediator in the pathogenesis of lobar pneumonia and parapneumonic effusion.
Abstract:
This study investigated the serum vascular endothelial growth factor (VEGF) levels in children with community-acquired pneumonia. Serum VEGF levels were measured in patients with pneumonia (n=29) and in control subjects (n=27) by a sandwich enzyme-linked immunosorbent assay. The pneumonia group was classified into bronchopneumonia with pleural effusion (n=1), bronchopneumonia without pleural effusion (n=15), lobar pneumonia with pleural effusion (n=4), and lobar pneumonia without pleural effusion (n=9) groups based on the findings of chest radiographs. We also measured serum IL-6 levels and the other acute inflammatory parameters. Serum levels of VEGF in children with pneumonia were significantly higher than those in control subjects (p<0.01). Children with lobar pneumonia with or without effusion showed significantly higher levels of serum VEGF than children with bronchopneumonia. For lobar pneumonia, children with pleural effusion showed higher levels of VEGF than those without pleural effusion. Children with a positive urinary S. pneumonia antigen test also showed higher levels of VEGF than those with a negative result. Serum IL-6 levels did not show significant differences between children with pneumonia and control subjects. Serum levels of VEGF showed a positive correlation with the erythrocyte sedimentation rate in the children with pneumonia. In conclusion, VEGF may be one of the key mediators that lead to lobar pneumonia and parapneumonic effusion.
Related Concept Videos
Respiratory Syncytial Virus Disease
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
